Sign in →

EPIC CODE: CDAU Drug Abuse Survey with Confirmation, Random, Urine

Reporting Name

Confirmed Drug Abuse Panel, U

Useful For

Detecting drug abuse involving amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, marijuana, opiates, and phencyclidine

 

This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
AMPHU Amphetamines Confirmation, U Yes No
OPATU Opiate Confirmation, U Yes No
BARBU Barbiturates Confirmation, U Yes No
COKEU Cocaine and metabolite Conf, U Yes No
ETOH Ethanol, U No No
PCPU Phencyclidine Confirmation, U Yes No
THCU Carboxy-THC Confirmation, U Yes No
BNZU Benzodiazepines Confirmation, U Yes No

Testing Algorithm

Testing begins with screening assays. If alcohol (ethanol) screen is positive, then the gas chromatography-flame ionization detector confirmation with quantification will be performed at an additional charge. If barbiturates, benzodiazepines, cocaine and metabolites, phencyclidine, or tetrahydrocannabinol metabolite screen is positive, then the gas chromatography-mass spectrometry (GC-MS) confirmation with quantification will be performed at an additional charge. Amphetamines and opiates that screen positive will be quantified with liquid chromatography-tandem mass spectrometry (LC-MS/MS) at an additional charge.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Urine

Specimen Required


Ordering Guidance


For situations where chain of custody is required, a Chain of Custody Kit (T282) is available. For chain-of-custody information, see CDAUX / Drug Abuse Panel with Confirmation, Chain of Custody, Urine.



Additional Testing Requirements


If urine creatinine is required or adulteration of the sample is suspected, the following test should be requested, ADULT / Adulterants Survey, Urine.



Specimen Required


Supplies: Urine Container, 60 mL (T313)

Collection Container/Tube: Plastic urine container

Submission Container/Tube: Plastic, 60-mL urine container (T313)

Specimen Volume: 30 mL

Collection Instructions:

1. Collect a random urine specimen.

2. Submit 30 mL in 1 plastic container.

3. No preservative.

Additional Information:

1. No specimen substitutions.

2. Additional drug panels and specific requests are available. Call 800-533-1710 or 507-266-5700.

3. Submitting less than 30 mL will compromise our ability to perform all necessary testing.


Specimen Minimum Volume

15 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 7 days
  Frozen  14 days

Reference Values

Negative

Screening cutoff concentrations

Amphetamines: 500 ng/mL

Barbiturates: 200 ng/mL

Benzodiazepines: 100 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Ethanol: 10 mg/dL

Opiates: 300 ng/mL

Phencyclidine: 25 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

Day(s) Performed

Monday through Saturday

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

80307

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CDAU Confirmed Drug Abuse Panel, U 87428-9

 

Result ID Test Result Name Result LOINC Value
30909 Alcohol 34180-0
2573 Amphetamines 43983-6
2574 Barbiturates 70155-7
2575 Benzodiazepines 16195-0
21652 Cocaine 19359-9
2577 Opiates 18390-5
2578 Phencyclidine 18392-1
2664 Tetrahydrocannabinol 19415-9
20672 Chain of Custody 77202-0

Clinical Information

This assay was designed to screen by immunoassay and confirm by gas chromatography-mass spectrometry (GC-MS), gas chromatography-flame ionization detection (GC-FID), or liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the following drugs:

-Amphetamines

-Barbiturates

-Benzodiazepines

-Cocaine

-Ethanol

-Opiates

-Phencyclidine

-Tetrahydrocannabinol

 

This assay represents the coupling of an immunoassay screen with an automatic confirmation of all positive results by the definitive assay available and described in each individual reflex test ID (eg, AMPHU / Amphetamines Confirmation, Urine). All positive screening results are confirmed by GC-MS, GC-FID, or LC-MS/MS and quantitated before a positive result is reported.

Interpretation

A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, AMPHU / Amphetamines Confirmation, Urine) for more information.

 

For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at https://www.mayocliniclabs.com/test-info/drug-book/index.html..

Cautions

Not intended for use in employment-related testing.

 

The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSS / Drug Screen, Prescription/OTC, Serum or PDSU / Drug Screen, Prescription/OTC, Urine).

Clinical Reference

1. Physician's Desk Reference (PDR). 60th edition. Montvale, NJ, Medical Economics Company, 2006

2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, McGraw-Hill Book Company, 2006

3. Langman LJ, Bechtel L, Holstege CP: Chapter 35. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. WB Saunders Company, 2011, pp 1109-1188

Method Description

The amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution (KIMS) as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.

 

ADH

 

Ethyl alcohol + NAD+ -----------------> acetaldehyde + NADH + H+

 

Report Available

Same day/1 to 2 days

Specimen Retention Time

2 weeks

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

NY State Approved

Yes

Method Name

CDAU: Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay

ETOH: Gas Chromatography-Mass Spectrophotometry (GC-MS)

Forms

If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.

Secondary ID

9446